ArticlePharmacological research2020

Rimeporide as a first- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy.

Stefano C Previtali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.